<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129151">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420809</url>
  </required_header>
  <id_info>
    <org_study_id>112285</org_study_id>
    <nct_id>NCT01420809</nct_id>
  </id_info>
  <brief_title>Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection</brief_title>
  <official_title>Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post-marketing surveillance study was designed to collect and assess the information on
      proper use of fondaparinux injection, such as the safety and efficacy under actual use
      conditions, in subjects undergoing orthopedic surgery of the lower limb at high risk of
      developing venous thromboembolism.

      (ARIXTRA® is a trademark of the GlaxoSmithKline group of companies.)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of incidences of adverse events in Japanese subjects undergoing orthopedic surgery of the lower limb</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events of bleeding</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence or absence of venous thromboembolism after treatment of fondaparinux</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1280</enrollment>
  <condition>Thromboembolism</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects undergoing orthopedic surgery of the lower limb at high risk of developing venous
        thromboembolism
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects undergo orthopedic surgery of the lower limb at high risk of developing
             venous thromboembolism

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 18, 2011</lastchanged_date>
  <firstreceived_date>July 28, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
